Evidence map›Paper›PMID 40998812›Full record

ArticleNPJ Parkinson's disease2025

Genome-wide association study of REM sleep behavior disorder in Parkinson's disease.

Yuri L Sosero, Karl Heilbron, Pierre Fontanillas, Lucy Norcliffe-Kaufmann, Eric Yu, Uladzislau Rudakou, Jennifer A Ruskey, Kathryn Freeman, Farnaz Asayesh, Kajsa A Brolin and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Yuri L SoseroDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Karl Heilbron23andMe, Inc., Sunnyvale, CA, USA.
Pierre Fontanillas23andMe, Inc., Sunnyvale, CA, USA.
Lucy Norcliffe-Kaufmann23andMe, Inc., Sunnyvale, CA, USA.
Eric YuDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Uladzislau RudakouDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Jennifer A RuskeyThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montréal, QC, Canada.
Kathryn FreemanThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montréal, QC, Canada.
Farnaz AsayeshThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montréal, QC, Canada.
Kajsa A BrolinLund University, Translational Neurogenetics Unit, Department of Experimental Medical Science, Lund, Sweden.
Maria SwanbergLund University, Translational Neurogenetics Unit, Department of Experimental Medical Science, Lund, Sweden.
Huw R MorrisDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Lesley WuDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Raquel RealDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Lasse PihlstrømDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Manuela TanDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Thomas GasserDepartment of Neurodegeneration at Hertie Institute for Clinical Brain Research, Tuebingen, Germany.
Kathrin BrockmannDepartment of Neurodegeneration at Hertie Institute for Clinical Brain Research, Tuebingen, Germany.
Hui LiuDepartment of Neurodegeneration at Hertie Institute for Clinical Brain Research, Tuebingen, Germany.
Michele T M HuOxford Parkinson's Disease Centre (OPDC), University of Oxford, Oxford, UK.
Donald G GrossetInstitute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, UK.
Simon J G LewisParkinson's Disease Research Clinic, Brain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia.
John B KwokParkinson's Disease Research Clinic, Brain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia.
Pau PastorUnit of Neurodegenerative Diseases, Department of Neurology, University Hospital Germans Trias i Pujol and The Germans Trias i Pujol Research Institute (IGTP) Badalona, Barcelona, Spain.
Ignacio AlvarezUnit of Neurodegenerative Diseases, Department of Neurology, University Hospital Germans Trias i Pujol and The Germans Trias i Pujol Research Institute (IGTP) Badalona, Barcelona, Spain.
Matej SkorvanekDepartment of Neurology, Pavol Jozef Šafárik University in Košice, Košice, Slovakia.
Alexandra LackovaDepartment of Neurology, Pavol Jozef Šafárik University in Košice, Košice, Slovakia.
Miriam OstrozovicovaDepartment of Neurology, Pavol Jozef Šafárik University in Košice, Košice, Slovakia.
Mie RizigUCL Queen Square Institute of Neurology, London, UK.
23andMe Research Team
International Parkinson’s Disease Genomics Consortium
Lynne KrohnDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Ziv Gan-OrDepartment of Human Genetics, McGill University, Montréal, QC, Canada. ziv.gan-or@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

REM sleep behavior disorder (RBD), is a prodromal synucleinopathy affecting a subset of Parkinson's disease (PD) patients and associated with neuropsychiatric symptoms. This study compared the genetic profiles of 13,020 PD patients with probable RBD (PD + RBD) and 5403 without (PD-RBD) using genome-wide association study (GWAS). RBD was assessed by questionnaires or self-reporting. Potential genetic correlations between neuropsychiatric traits and PD + RBD were assessed using linkage disequilibrium score regression. The top variant in the SNCA locus was associated with PD + RBD (rs10005233-T, OR = 1.21, 95% CI = 1.16-1.27, p = 1.81e-15). PD risk variants in SNCA (rs5019538-G, OR = 0.85, 95% CI = 0.81-0.89, p = 2.46e-10; rs356182-G, OR = 0.89, 95% CI = 0.84-0.95, p = 0.0001) and LRRK2 loci (rs34637584, OR = 0.41, 95% CI = 0.28-0.61, p = 1.04e-5) were associated with reduced PD + RBD risk. A suggestive genetic correlation between attention deficit hyperactivity disorder and PD + RBD was observed but was not statistically significant after correction. These findings highlight genetic distinctions between PD + RBD and PD-RBD, offering insights into PD stratification and potential subtype-specific treatments.

Identifiers

PMID40998812
PMCPMC12462436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.